Eine Forschungsstudie, um zu sehen, wie gut CagriSema im Vergleich zu Semaglutid, Cagrilintid und Placebo den Blutzucker und das Körpergewicht bei Menschen mit Typ-2-Diabetes senkt, die mit Metformin mit oder ohne SGLT2-Inhibitor behandelt werden (REIMAGINE 2)
Wirksamkeit und Sicherheit von gleichzeitig verabreichtem Cagrilintid und Semaglutid (CagriSema) s.c. in Dosen von 2,4/2,4 mg und 1,0/1,0 mg einmal wöchentlich im Vergleich zu Semaglutid 2,4 mg und 1,0 mg, Cagrilintid 2,4 mg und Placebo bei Teilnehmern mit Typ-2-Diabetes, der mit Metformin mit oder ohne SGLT2-Inhibitor unzureichend kontrolliert wurde
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1023AAB
- STAT Research
-
Buenos Aires, Argentinien, C1425AGC
- Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
-
CABA, Argentinien, C1061AAS.
- CIPREC Arenales
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentinien, C1128 AAF
- Mautalen Salud e investigación
-
-
City of Buenos Aires
-
CABA, City of Buenos Aires, Argentinien, C1180AAX
- Sanatorio Güemes
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinien, S2000CUD
- Instituto de Investigaciones Clínicas Rosario
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Charles Perkins Centre
-
Darlinghurst, New South Wales, Australien, 2010
- Momentum Clinical Research Darlinghurst
-
Macquarie Park, New South Wales, Australien, 2109
- Macquarie University - Clinical Trials Unit
-
Merewether, New South Wales, Australien, 2291
- Hunter Diabetes Centre
-
-
Queensland
-
Meadowbrook, Queensland, Australien, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australien, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- St Vincent's Hospital Melbourne - Endocrinology & Diabetes Department
-
Melbourne, Victoria, Australien, 3004
- Baker Heart and Diabetes Institute
-
-
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80030-480
- Cline Research Center
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01228-200
- CPCLIN - Centro de Pesquisas Clínicas
-
São Paulo, São Paulo, Brasilien, 01228-000
- CPHosp Medicina, Ensino e Pesquisa Ltda
-
-
-
-
-
Burgas, Bulgarien, 8000
- IPSMC - Dr. Nikolay Kostadinov EOOD
-
Gotse Delchev, Bulgarien, 2900
- Dr. Tatyana Metalova - AIPSMCE EOOD
-
Kardzhali, Bulgarien, 6600
- ASOMCEID - Individual Practice - Dr. Abdul-Azis EOOD
-
Lom, Bulgarien, 3600
- Medical Center Zdrave Lom EOOD
-
Razgrad, Bulgarien, 7200
- Medical Centre Razgrad OOD
-
Sofia, Bulgarien, 1202
- DCC Ascendent OOD
-
Sofia, Bulgarien, 1756
- Medical Center Maraya Med EOOD
-
Varna, Bulgarien, 9000
- Medical centre Clinic Nova
-
Varna, Bulgarien, 9000
- Medical Centre - Clinic Nova EOOD
-
Varna, Bulgarien, 9010
- UMHAT Sveta Marina EAD, Clinic of Internal Diseases
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100050
- Beijing Friendship Hospital, Capital Medical University-Endocrinology
-
Beijing, Beijing Municipality, China, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 404000
- Chongqing University Three Gorges Hospital
-
-
Henan
-
Kaifeng, Henan, China, 475000
- Huaihe Hospital of Henan University-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Suzhou, Jiangsu, China, 215002
- Suzhou Municipal Hospital-Endocrinology
-
Zhenjiang, Jiangsu, China, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, China, 250000
- Jinan Central Hospital
-
Jinan, Shandong, China, 250013
- Jinan Central Hospital
-
-
-
-
-
Berlin, Deutschland, 13597
- Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
-
Daaden, Deutschland, 57567
- Diabetologische Schwerpunktpraxis Daaden
-
Dortmund, Deutschland, 44137
- Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
-
Dresden, Deutschland, 01307
- Uniklinik TU Dresden - Med. Klinik III
-
Elsterwerda, Deutschland, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Essen, Deutschland, 45136
- InnoDiab Forschung GmbH
-
Gelnhausen, Deutschland, 63571
- MVZ Diabeteszentrum Dr. Tews GmbH
-
Hamburg, Deutschland, 22041
- Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR
-
Hamburg, Deutschland, 21109
- Diabetes-Zentrum-Wilhelmsburg GbR
-
Lingen, Deutschland, 49808
- Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
-
Ludwigshafen, Deutschland, 67059
- Die Praxis am Ludwigsplatz
-
Lübeck, Deutschland, 23538
- Uniklinik Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
-
München, Deutschland, 81667
- Medicover Neuroendokrinologie MVZ München
-
Oldenburg in Holstein, Deutschland, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
Zwenkau, Deutschland, 04442
- Praxis für Innere Medizin - Zwenkau
-
-
-
-
-
Aarhus N, Dänemark, 8200
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus
-
Copenhagen, Dänemark, 2400
- Bispebjerg Hospital, IC-Forskning
-
Herlev, Dänemark, 2730
- Steno Diabetes Center Copenhagen
-
Hillerød, Dänemark, 3400
- Hillerød Endokrinologisk amb. H0652
-
Hvidovre, Dänemark, 2650
- Hvidovre Hospital Endokrinologisk forsk. afs. 159
-
Odense C, Dänemark, 5000
- Steno Diabetes Center Odense
-
-
-
-
-
Jyväskylä, Finnland, 40100
- Terveystalo Jyväskylä
-
Seinäjoki, Finnland, 60220
- Seinäjoen keskussairaala
-
Tampere, Finnland, 33100
- Pihlajalinna Koskiklinikka
-
Tampere, Finnland, 33100
- Terveystalo Tampere Rautatienkatu
-
Turku, Finnland, 20520
- Turku University Hospital
-
-
-
-
-
Athens, Griechenland, 11527
- "Laiko" General Hospital of Athens
-
Athens, Griechenland, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Griechenland, 15125
- Iatriko Athinon (Athens Medical Canter)
-
Athens, Griechenland, 11527
- General hospital of Athens 'G.Gennimatas'
-
Larissa, Griechenland, 41110
- Univ Gen Hospital Larisa
-
Thessaloniki, Griechenland, 54636
- "AHEPA" University Hospital of Thessaloniki
-
Thessaloniki, Griechenland, 54642
- "Ippokrateio" G.H. of Thessaloniki
-
Thessaloniki, Griechenland, 54621
- "AHEPA" University Hospital of Thessaloniki
-
Thessaloniki, Griechenland, 54645
- NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes
-
-
Attica
-
Athens, Attica, Griechenland, 12462
- University Hospital of Athens ATTIKON
-
-
Thessaloniki
-
Nea Efkarpia, Thessaloniki, Griechenland, 56429
- General Hospital Of Thessaloniki Papageorgiou
-
-
-
-
-
Chandigarh, Indien, 160012
- Post Graduate Institute of Medical Education & Research
-
New Delhi, Indien, 110001
- Lady Hardinge Medical College
-
-
Andhra Pradesh
-
Vijaywada, Andhra Pradesh, Indien, 520002
- Yalamanchi Hospitals and Research centres pvt ltd
-
-
Assam
-
Guwahati, Assam, Indien, 781032
- Gauhati Medical College and Hospital
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 390013
- Swasthya Diabetes Care
-
-
Karnataka
-
Bengaluru, Karnataka, Indien, 560066
- Lifecare Hospital and Research Centre
-
Mysuru, Karnataka, Indien, 570001
- K R Hospital
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400008
- BYL Nair Hospital and T N Medical College Department of endo
-
Thane, Maharashtra, Indien, 421004
- Ashirwad Hospital and Research Centre
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302004
- SMS Medical College & Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indien, 600086
- Madras Diabetes Research Foundation
-
Coimbatore, Tamil Nadu, Indien, 641018
- KG Hospital
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500004
- Gleneagles Hospitals
-
Hyderabad, Telangana, Indien, 50082
- Dr P V Rao - Diabetes Research Centre
-
-
West Bengal
-
Kolkata, West Bengal, Indien, 700054
- Apollo Multispeciality Hospital, Kolkata
-
-
-
-
-
Haifa, Israel, 35152
- Linn clinic - Clalit Health Services
-
Haifa, Israel, 35152
- Linn clinic - Diabetes Unit
-
Herzliya, Israel, 4630945
- Clalit sick fund Herzlia
-
Holon, Israel, 58100
- Wolfson MC - Diabetes Clinic
-
Jerusalem, Israel, 91120
- Hadassah Ein Karam MC - Diabetes Unit
-
Rehovot, Israel, 76100
- Kaplan MC - Metabolic Unit
-
Rehovot, Israel, 76100
- Kaplan MC
-
Tel HaShomer, Israel, 52621
- Sheba MC - Endocrinology Clinic
-
-
Israel
-
Herzeliya, Israel, Israel, 4630945
- Clalit sick fund Herzeliya
-
-
-
-
-
Arezzo, Italien, 52100
- Azienda Sanitaria Usl Toscana Sud Est - Ospedale San Donato
-
Bergamo, Italien, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Italien, 88100
- Azienda Ospedaliero-Universitaria Renato Dulbecco
-
Chieti Scalo, Italien, 66100
- Università degli studi G. D'Annunzio Chieti Pescara - CAST
-
Milan, Italien, 20157
- Azienda Ospedaliera Luigi Sacco
-
Naples, Italien, 80131
- Azienda Ospedaliera Universitaria Federico II di Napoli
-
Palermo, Italien, 90127
- Dip. di Medicina Interna Policlinico Universitario Palermo
-
Palermo, Italien, 90127
- AOUP Giaccone Palermo
-
Roma, Italien, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
Verona, Italien, 37126
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento
-
-
Fi
-
Florence, Fi, Italien, 50134
- AOU Careggi Firenze
-
-
Lazio
-
Rome, Lazio, Italien, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Dipartimento di scienze Mediche e Chirurgiche
-
-
MI
-
Milan, MI, Italien, 20132
- Istituto Scientifico San Raffaele
-
-
Tuscany
-
Florence, Tuscany, Italien, 50134
- AOU Careggi Firenze
-
-
-
-
-
Chiba-shi, Chiba, Japan, 260-0804
- Akaicho Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Mito-shi, Ibaraki, Japan, 311-4153
- Minami Akatsuka Clinic_internal medicine
-
Osaka-shi, Osaka, Japan, 530-8480
- Medical Research Institute KITANO HOSPITAL_Diabetes & Endocrinology
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Fukushima, Japan
-
Koriyama-shi, Fukushima, Fukushima, Japan, Japan, 963-8851
- Seino Internal Medicine Clinic_Internal medicine
-
-
Japan
-
Oita-shi, Oita,, Japan, Japan, 870 0039
- Abe Diabetes Clinic_Internal Medicine
-
-
-
-
-
Québec, Kanada, G1W 4R4
- Centre de Recherche Saint-Louis
-
Québec, Kanada, G1V 4W2
- Clinique des Maladies Lipidiques de Quebec Inc.
-
Québec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
-
Alberta
-
Calgary, Alberta, Kanada, T2H 2G4
- Centricity Research Calgary
-
Calgary, Alberta, Kanada, T2H 2G4
- Centricity Research Calgary Endocrinology
-
Sherwood Park, Alberta, Kanada, T8H 0N2
- Synergy Wellness Clinic
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3Z 2N6
- Ocean West Research Clinic
-
Surrey, British Columbia, Kanada, V4A 0C1
- Hilltop Medical Clinic
-
Surrey, British Columbia, Kanada, V3R 4H6
- Guilford Med Clinic
-
Surrey, British Columbia, Kanada, V3T0X6
- Unity Healthcare Clinic
-
Vancouver, British Columbia, Kanada, V6Z 2T1
- Spectrum Health Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Ontario
-
Barrie, Ontario, Kanada, L4N 7L3
- Centricity Res. Barrie Endo
-
Brampton, Ontario, Kanada, L6S 0C6
- Centricity Research Brampton Endocrinology
-
Concord, Ontario, Kanada, L4K 4M2
- Centricity Research Vaughn Endocrinology
-
Courtice, Ontario, Kanada, L1E2J5
- Medical Trust Clinics, Inc.
-
Etobicoke, Ontario, Kanada, M9R 4E1
- Centricity Research Etobicoke Endocrinology
-
London, Ontario, Kanada, N5W 6A2
- Milestone Research
-
London, Ontario, Kanada, N6G 2M1
- Western Univ. Cnt for Studies in Fam Med
-
Markham, Ontario, Kanada, L3P 7P2
- My Endo Diabetes & Endo Cent
-
Nepean, Ontario, Kanada, K2J 0V2
- Centricity Research Ottawa LMC
-
Oshawa, Ontario, Kanada, L1J 2K9
- Centricity Research Oshawa
-
Toronto, Ontario, Kanada, M6G 1M2
- Diabetes Heart Research Centre
-
Toronto, Ontario, Kanada, M4G 3E8
- Centricity Research Toronto
-
-
Quebec
-
Montreal, Quebec, Kanada, H4N 2W2
- Centre Medical Acadie
-
Pointe-Claire, Quebec, Kanada, H9R 4S3
- Centricity Res Pointe-Claire
-
Québec, Quebec, Kanada, G3K 2P8
- ALPHA Recherche Clinique
-
Saint-Laurent, Quebec, Kanada, H4T 1Z9
- LMC Clin Rsrch Inc. (Montreal)
-
Sherbrooke, Quebec, Kanada, J1J 2G2
- Q & T Research Sherbrooke Inc.
-
Terrebonne, Quebec, Kanada, J6X 4P7
- Ctr de Med Metab de Lanaudiere
-
Victoriaville, Quebec, Kanada, G6P 3Z8
- Diex Recherche Victoriaville
-
-
-
-
-
Barranquilla, Kolumbien, 80001
- Cimedical
-
Cali, Kolumbien, 760042
- Clinica Imbanco SAS
-
Montería, Kolumbien, 230001
- IMAT - Oncomedica
-
-
Santander Department
-
Floridablanca, Santander Department, Kolumbien, 681004
- FOSCAL
-
-
-
-
-
Opatija, Kroatien, 51 410
- Specijalna bolnica Thalassotherapia
-
Slavonski Brod, Kroatien, 35 000
- General Hospital Dr. Josip Bencevic_Diabetic department
-
Varaždin, Kroatien, 42 000
- Opca bolnica Varazdin_Endocrinology
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatien, 10000
- Poliklinika Solmed
-
-
County of Osijek-Baranja
-
Osijek, County of Osijek-Baranja, Kroatien, 31000
- Poliklinika SLAVONIJA OSIJEK
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Kroatien, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexiko, 21200
- Centro de investigación en Artritis y Osteoporosis S.C.
-
-
Jalisco
-
Guadalajara, Jalisco, Mexiko, 44670
- Centro de Investigacion Clinica Endocrinologica de Jalisco
-
Guadalajara, Jalisco, Mexiko, 44600
- Instituto Jalisciense de Investigación en Diabetes y Obesidad
-
-
Tamaulipas
-
Ciudad Madero, Tamaulipas, Mexiko, 89440
- Centro de Estudios de Investigación Metabólicos y Cardio
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Centrum Medyczne Pratia Bydgoszcz
-
Dąbrowa Górnicza, Polen, 41-300
- PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
-
Lublin, Polen, 20-362
- Velocity Nova Sp. z o.o.
-
Puławy, Polen, 24-100
- KO-MED Centra Kliniczne Sp. z o.o.
-
Staszów, Polen, 28-200
- Velocity Nova Sp. z o.o.
-
Warsaw, Polen, 02-117
- Instytut Diabetologii Sp. z o.o.
-
Warsaw, Polen, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Polen, 00-710
- NBR Polska Tomasz Klodawski
-
Zgierz, Polen, 95-100
- Zgierskie Centrum Kardiologii Med-Pro Polsko-Amerykańskich Klinik Serca
-
-
Lesser Poland Voivodeship
-
Chrzanów, Lesser Poland Voivodeship, Polen, 32-500
- Malopolskie Centrum Sercowo-Naczyniowe
-
-
Lubusz Voivodeship
-
Gorzów Wielkopolski, Lubusz Voivodeship, Polen, 66-400
- Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
-
-
Masovian Voivodeship
-
Żyrardów, Masovian Voivodeship, Polen, 96-300
- Prywatna Praktyka Lekarska Anna Chudoba
-
-
Mazovian Voivodeship
-
Warsaw, Mazovian Voivodeship, Polen, 02-117
- Instytut Diabetologii Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polen, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-435
- NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
-
Bialystok, Podlaskie Voivodeship, Polen, 15-351
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik
-
-
Silesian Voivodeship
-
Dąbrowa Górnicza, Silesian Voivodeship, Polen, 41-300
- PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
-
Tychy, Silesian Voivodeship, Polen, 43-100
- PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
-
-
Świętokrzyskie Voivodeship
-
Staszów, Świętokrzyskie Voivodeship, Polen, 28-200
- Velocity Nova Sp. z o.o.
-
-
-
-
-
Bacau, Rumänien, 600154
- CMI Dr. Pletea Noemi SRL
-
Brasov, Rumänien, 500283
- Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed
-
Brasov, Rumänien, 500101
- Mariodiab Clinic SRL
-
Bucharest, Rumänien, 050913
- Diabet Med SRL
-
Craiova, Rumänien, 200349
- Urodiamed SRL
-
Galati, Rumänien, 800001
- S.C Milena Sante SRL
-
Mangalia, Rumänien, 905500
- Gama Diamed Srl
-
Paşcani, Rumänien, 705200
- Bella Praxis S.R.L.
-
-
Argeş
-
Piteşti, Argeş, Rumänien, 110283
- Cabinet Medical Individual Dr. Ramona Dragut SRL
-
-
Bucurestii
-
Bucharest, Bucurestii, Rumänien, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumänien, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Reghin, Mureș County, Rumänien, 545300
- Poli Cardinal Med Srl
-
-
Prahova
-
Ploieşti, Prahova, Rumänien, 100179
- Diabmed Dr Popescu Alexandrina SRL
-
Ploieşti, Prahova, Rumänien, 100342
- CMI Dr. Busegeanu Mihaela Magdalena
-
-
Sălaj County
-
Zalău, Sălaj County, Rumänien, 450112
- Cabinet Medical de Diabet, Nutritie si Boli Metabolice-Dr. Zaharie Daniela Gabriela
-
-
-
-
-
Linköping, Schweden, 582 13
- CTC EbbePark Linköping
-
Lund, Schweden, 222 42
- Skåne US - Endokrinologkliniken Lund
-
Lund, Schweden, 222 21
- Clemenstorgets Hjärtmottagning
-
Malmö, Schweden, 205 02
- Skåne US - Forskningsmottagning Internmedicin (tidigare KFE)
-
Mölndal, Schweden, 431 53
- CTC GoCo Mölndal
-
Stockholm, Schweden, 171 64
- KS Solna - FOU hjärta- kärl Mottagningen
-
Örebro, Schweden, 701 85
- Örebro US - Överviktsenheten
-
-
-
-
-
Belgrade, Serbien, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Serbien, 11000
- Endocrinology, Diabetes and Metabolism Diseases Clinic
-
Belgrade, Serbien, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Kragujevac, Serbien, 34000
- Clinical Centre Kragujevac, Internal Diseases Clinic, Endocr
-
Kragujevac, Serbien, 34000
- Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbien, 21000
- Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
-
-
-
-
-
Bardejov, Slowakei, 08501
- DIADA, s.r.o.
-
Košice, Slowakei, 040 01
- Diabetologicka ambulancia DIOLI s.r.o.
-
Košice, Slowakei, 040 01
- DIOLI s.r.o.
-
Malacky, Slowakei, 90101
- MediVet s.r.o.
-
Prešov, Slowakei, 080 01
- DIALIPID, s.r.o.
-
Prievidza, Slowakei, 971 01
- MUDr. Jan Culak, s.r.o.
-
Ružomberok, Slowakei, 034 01
- DIACENTRUM, s.r.o.
-
Sabinov, Slowakei, 08301
- MEDI-DIA s.r.o.
-
Sabinov, Slowakei, 083 01
- MEDI-DIA s.r.o.
-
Trebišov, Slowakei, 075 01
- ARETEUS s.r.o.
-
Šurany, Slowakei, 942 01
- DEImedi, s. r. o.
-
Žiar nad Hronom, Slowakei, 965 01
- iDia s. r. o.
-
-
-
-
-
Koper, Slowenien, 6000
- Healthcare Centre Koper
-
Kočevje, Slowenien, 1330
- Healthcare centre Kocevje
-
Ljubljana, Slowenien, 1000
- UKC Ljubljana, Endocrinology and Diabetes
-
Ljubljana, Slowenien, 1000
- Dermatologija Bartenjev
-
Maribor, Slowenien, 2000
- UKC Maribor - diabetes
-
Nova Gorica, Slowenien, 5000
- Healthcare Centre Nova Gorica
-
Sempeter pri Gorici, Slowenien, 5290
- General Hospital Nova Gorica_Diabetes
-
Topolšica, Slowenien, 3326
- Hospital Topolšica
-
-
-
-
-
A Coruña, Spanien, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Spanien, 08035
- Hospital Vall d'Hebron
-
Móstoles, Spanien, 28935
- Hospital Universitario de Móstoles
-
Palma de Mallorca, Spanien, 07198
- Hospital Son Llatzer
-
Segovia, Spanien, 40002
- Hospital General de Segovia
-
Seville, Spanien, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
Valencia, Spanien, 46026
- Hospital La Fe_Endocrinología y Nutrición
-
-
Barcelona
-
La Roca Del Vallés, Barcelona, Spanien, 08430
- ABS La Roca CAP Vicenç_Endocrino
-
-
-
-
Eastern Cape
-
Port Elizabeth, Eastern Cape, Südafrika, 6001
- Phoenix Pharma
-
-
Gauteng
-
Johannesburg, Gauteng, Südafrika, 2001
- Newtown Clinical Research
-
Johannesburg, Gauteng, Südafrika, 2196
- Sandton Medical Research
-
Kempton Park, Gauteng, Südafrika, 1619
- Clinresco Centres (Pty) Ltd
-
Pretoria, Gauteng, Südafrika, 0186
- Clinical Trial Systems (CTC)
-
-
Western Cape
-
Paarl, Cape Town, Western Cape, Südafrika, 7646
- Paarl Research Centre
-
-
-
-
-
Daegu, Südkorea, 42415
- Yeungnam University Medical Center
-
Gwangju, Südkorea, 501-717
- Chosun University Hospital
-
Seoul, Südkorea, 03080
- Seoul National University Hospital
-
Seoul, Südkorea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Südkorea, 02841
- Korea University Anam Hospital
-
Seoul, Südkorea, 02447
- Kyunghee University Medical Center
-
-
Gyeonggi-do
-
Bucheon-si, Gyeonggi-do, Südkorea, 14647
- The Catholic University of Korea, Bucheon ST. Mary's Hospital
-
-
-
-
-
Changhua, Taiwan, 500
- Changhua Christian Hospital_Metabolic Dept.
-
Taipei, Taiwan, 110
- Taipei Medical University Hospital
-
-
-
-
-
Brno, Tschechien, 602 00
- Fakultní nemocnice U sv. Anny v Brně
-
Broumov, Tschechien, 550 01
- Edumed Broumov
-
Holešov, Tschechien, 76901
- Diahaza s.r.o.
-
Plzeň 3, Tschechien, 301 00
- DIALINE s.r.o.
-
Prague, Tschechien, 110 00
- Diabet2 s.r.o.
-
Prague, Tschechien, 140 00
- MUDr. Michala Pelikanova
-
-
Czech Republic
-
Prague, Czech Republic, Tschechien, 140 21
- IKEM Centrum Diabetologie
-
-
-
-
-
Adana, Türkei (türkiye), 01790
- Cukurova Universitesi Tip Fakultesi
-
Adana, Türkei (türkiye), 01790
- Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi- Endokrinoloji
-
Antalya, Türkei (türkiye), 07058
- Akdeniz University Tip Fakultesi Hastanesi
-
Antalya, Türkei (türkiye), 07058
- Akdeniz Üniversitesi Hastanesi- Endokrinoloji
-
Eskişehir, Türkei (türkiye), 26040
- Eskisehir Osmangazi University School of Medicine
-
Eskişehir, Türkei (türkiye), 26040
- Eskişehir Osmangazi Üniversitesi Sağlık, Uygulama ve Araştırma Hastanesi
-
Istanbul, Türkei (türkiye), 34371
- Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi
-
Istanbul, Türkei (türkiye), 34390
- Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji
-
Istanbul, Türkei (türkiye), 34722
- T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
-
Istanbul, Türkei (türkiye), 34098
- Haseki Sultangazi
-
Istanbul, Türkei (türkiye), 34371
- Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi- Seyrantepe Yerleşkesi- Endokrinoloji
-
Istanbul, Türkei (türkiye), 34722
- Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye
-
Istanbul, Türkei (türkiye), 34098
- Haseki Eğitim ve Araştırma Hastanesi- Dahiliye
-
Istanbul, Türkei (türkiye), 34390
- İstanbul Üniversitesi İstanbul Tıp Fakültesi Hastanesi- Endokrinoloji
-
Istanbul, Türkei (türkiye), 34480
- Başakşehir Çam ve Sakura Şehir Hastanesi
-
Istanbul, Türkei (türkiye), 34480
- Basaksehir Cam ve Sakura Sehir Hastanesi
-
Rize, Türkei (türkiye), 53020
- Recep Tayyip Erdoğan Üni. Eğitim ve Araştırma Hastanesi
-
Rize, Türkei (türkiye), 53020
- Recep Tayyip Erdoğan Üniversitesi EAH-Endokrinoloji
-
Tekirdağ, Türkei (türkiye), 59030
- Tekirdag Namık Kemal UTF
-
Tekirdağ, Türkei (türkiye), 59030
- Tekirdağ Namık Kemal Üniversitesi Hastanesi- Dahiliye
-
-
-
-
-
Budapest, Ungarn, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Ungarn, 1134
- MH Egészségügyi Központ
-
Kaposvár, Ungarn, 7400
- Kaposi Mór Oktató Kórház
-
Nagykanizsa, Ungarn, 8800
- Kanizsai Dorottya Kórház
-
Szombathely, Ungarn, 9700
- Vas Vármegyei Markusovszky Egyetemi Oktatókórház
-
Zalaegerszeg, Ungarn, 8900
- Zala Megyei Szent Rafael Kórház
-
-
Csongrád-Csanád
-
Szeged, Csongrád-Csanád, Ungarn, 6725
- Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Debreceni Egyetem Belgyógyászati Klinika
-
-
Pest County
-
Budapest, Pest County, Ungarn, 1036
- Óbudai Egészségügyi Centrum
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Univ of Alabama_Birmingham
-
Birmingham, Alabama, Vereinigte Staaten, 35211
- Synexus Clin Res-Birmingham
-
Pelham, Alabama, Vereinigte Staaten, 35124
- Cahaba Research
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85006
- Velocity Clinical Research-Phoenix
-
Phoenix, Arizona, Vereinigte Staaten, 85020
- Synexus Rsch /Cnt Phnx Med C
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Arkansas Clinical Research
-
-
California
-
Banning, California, Vereinigte Staaten, 92220
- Velocity Clinical Res-Banning
-
Chula Vista, California, Vereinigte Staaten, 91911
- Velocity Clin Res-Chula Vista
-
Concord, California, Vereinigte Staaten, 94520
- John Muir Physicians Network
-
Escondido, California, Vereinigte Staaten, 92025
- Headlands Research California, LLC
-
Gardena, California, Vereinigte Staaten, 90247
- Velocity Clin Res Gardena
-
La Mesa, California, Vereinigte Staaten, 91942
- Velocity Clin Res San Diego
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda Univ Hlth Cr Endo
-
Mission Hills, California, Vereinigte Staaten, 91345
- Facey Medical Foundation
-
Palm Springs, California, Vereinigte Staaten, 92262
- Desert Oasis Hlthcr Med Group
-
San Bernardino, California, Vereinigte Staaten, 92408
- Velocity Clin Res- San Bern
-
San Diego, California, Vereinigte Staaten, 92111
- Linda Vista Health Care Ctr
-
Santa Ana, California, Vereinigte Staaten, 92704
- Velocity Clin Res Santa Ana
-
Toluca Lake, California, Vereinigte Staaten, 91602
- Premier Medical Center, Inc.
-
Van Nuys, California, Vereinigte Staaten, 91405
- Velocity Clin Res - Panorama
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten, 80906
- Optumcare Clinical Trials,LLC-Golden
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32204
- Northeast Research Institute
-
Miami, Florida, Vereinigte Staaten, 33165
- New Horizon Research Center
-
Miami, Florida, Vereinigte Staaten, 33144
- Clinical Trial Services Corp
-
Miami, Florida, Vereinigte Staaten, 33155
- Bioclinical Research Alliance
-
Miramar, Florida, Vereinigte Staaten, 33027
- South Broward Research LLC
-
Ocoee, Florida, Vereinigte Staaten, 34761
- West Orange Endocrinology
-
Orange City, Florida, Vereinigte Staaten, 32763
- Optimal Research Sites
-
Orlando, Florida, Vereinigte Staaten, 32804
- AdventHealth Diab Inst
-
Orlando, Florida, Vereinigte Staaten, 32804
- Advent Health-Res Inst
-
Orlando, Florida, Vereinigte Staaten, 32806
- Synexus Clin Res - Orlando
-
Oviedo, Florida, Vereinigte Staaten, 32765
- Oviedo Medical Research, LLC
-
-
Georgia
-
Conyers, Georgia, Vereinigte Staaten, 30094
- Hope Clin Res & Wellness
-
Macon, Georgia, Vereinigte Staaten, 31210
- East Coast Institute for Res
-
Marietta, Georgia, Vereinigte Staaten, 30067
- Urban Family Practice Assoc
-
Roswell, Georgia, Vereinigte Staaten, 30076
- Endocrine Research Solutions, Inc.
-
Roswell, Georgia, Vereinigte Staaten, 30076
- Endocrine Research Solutions
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Pacific Diabetes & Endo Ctr
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83702
- St. Luke's Health System
-
Meridian, Idaho, Vereinigte Staaten, 83646
- Solaris Clinical Research
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60607
- Cedar-Crosse Research Center
-
Gurnee, Illinois, Vereinigte Staaten, 60031
- Clinical Invest Special_Gurnee
-
Skokie, Illinois, Vereinigte Staaten, 60077
- Evanston Premier Hlthcr Res
-
Skokie, Illinois, Vereinigte Staaten, 60077
- Endeavor Health
-
-
Iowa
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Iowa Diabetes & Endo Res Ctr
-
-
Kansas
-
Newton, Kansas, Vereinigte Staaten, 67114
- Alliance for Multispec Res
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Cotton-O'Neil Diab & Endo Ctr
-
-
Louisiana
-
Lafayette, Louisiana, Vereinigte Staaten, 70508
- Velocity Clin Res Lafayette
-
-
Massachusetts
-
New Bedford, Massachusetts, Vereinigte Staaten, 02740
- BTC of New Bedford, LLC
-
-
Mississippi
-
Gulfport, Mississippi, Vereinigte Staaten, 39503
- Velocity Clin Res Gulfport
-
-
Missouri
-
Chesterfield, Missouri, Vereinigte Staaten, 63017
- Diabetes & Endo Specialists Inc
-
-
New Jersey
-
Trenton, New Jersey, Vereinigte Staaten, 08611
- Premier Research Inc.
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87107
- Velocity Clin Res Albuquerque
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12203
- AMC Community Endocrinology
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Velocity Clin Res Syracuse
-
West Seneca, New York, Vereinigte Staaten, 14224
- Southgate Medical Group, LLP
-
Westfield, New York, Vereinigte Staaten, 14787
- Great Lakes Medical Research
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- University of North Carolina
-
Greensboro, North Carolina, Vereinigte Staaten, 27408
- PharmQuest Life Sciences LLC
-
Morehead City, North Carolina, Vereinigte Staaten, 28557
- Carteret Medical Group
-
Statesville, North Carolina, Vereinigte Staaten, 28625
- Piedmont Healthcare/Research
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Accellacare
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44311
- Synexus Clinical Research US, Inc
-
Columbus, Ohio, Vereinigte Staaten, 43213
- Centricity Research
-
-
Oklahoma
-
Norman, Oklahoma, Vereinigte Staaten, 73069
- Alliance for Multispec Res
-
-
Rhode Island
-
Cumberland, Rhode Island, Vereinigte Staaten, 02864
- Clinical Res Collaborative
-
East Greenwich, Rhode Island, Vereinigte Staaten, 02818
- Velocity Clin Res Providence
-
-
South Carolina
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- Synexus Clin Res US-Anderson
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- AnMed Health IMA
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- Velocity Clinical Res-Anderson
-
Gaffney, South Carolina, Vereinigte Staaten, 29340
- Velocity Clin Res Gaffney
-
Simpsonville, South Carolina, Vereinigte Staaten, 29681-1538
- Hillcrest Clinical Research
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Spartanburg Medical Research
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Velocity Clin Res Spartanburg
-
-
Tennessee
-
Bristol, Tennessee, Vereinigte Staaten, 37620-7352
- Holston Medical Group Pc
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Holston Medical Group
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Clinical Research Associates
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten, 76012-4637
- Arlington Family Res. Ctr Inc
-
Austin, Texas, Vereinigte Staaten, 78759
- Velocity Clin Res Austin
-
Bellaire, Texas, Vereinigte Staaten, 77401
- UT Health University of Texas
-
Dallas, Texas, Vereinigte Staaten, 75231
- North Texas Endocrine Center
-
Dallas, Texas, Vereinigte Staaten, 75251
- Cedar Health Research
-
Dallas, Texas, Vereinigte Staaten, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Vereinigte Staaten, 75234
- Synexus Clin Res Dallas
-
Houston, Texas, Vereinigte Staaten, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Vereinigte Staaten, 77061
- Synergy Groups Medical
-
Houston, Texas, Vereinigte Staaten, 77040
- JCCT- Juno NW Houston
-
Katy, Texas, Vereinigte Staaten, 77450
- Medical Colleagues-Texas LLP
-
Kerrville, Texas, Vereinigte Staaten, 78028
- Sante Clinical Research
-
Missouri City, Texas, Vereinigte Staaten, 77459
- Discovery MM Services, INC Missouri
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University of Texas San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78233
- NE Clin Res of San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78229
- AES San Antonio
-
Shavano Park, Texas, Vereinigte Staaten, 78231
- Consano Clinical Research, LLC
-
Tomball, Texas, Vereinigte Staaten, 77375
- DM Clin Rsrch/Fam Diag Clinic
-
-
Utah
-
Sandy City, Utah, Vereinigte Staaten, 84093
- Diabetes & Endo Treatment Spec
-
West Jordan, Utah, Vereinigte Staaten, 84088
- Velocity Clin Res-Salt Lk City
-
-
Virginia
-
Newport News, Virginia, Vereinigte Staaten, 23606
- TPMG Clinical Research
-
-
Washington
-
Renton, Washington, Vereinigte Staaten, 98057
- Rainier Clin Res Ctr Inc
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- St. Vincent Hosp-Prevea Health
-
-
-
-
-
Aberdeen, Vereinigtes Königreich, AB25 2ZP
- Aberdeen Royal Infirmary
-
Aberdeen, Vereinigtes Königreich, AB25 2ZP
- Aberdeen Royal Infirmary - Diabetes
-
Bath, Vereinigtes Königreich, BA2 3HT
- Oldfield Surgery
-
Blackburn, Vereinigtes Königreich, BB2 1AX
- Oakenhurst Medical Practice
-
Dundee, Vereinigtes Königreich, DD1 9SY
- Ninewells Hospital
-
Liverpool, Vereinigtes Königreich, L9 7AL
- Aintree University Hospital
-
Norwich, Vereinigtes Königreich, NR4 7UY
- Norfolk and Norwich University Hospital Trust
-
Southampton, Vereinigtes Königreich, SO30 3JB
- Moorgreen Hospital
-
Swansea, Vereinigtes Königreich, SA2 8PP
- Joint Clinical Research Facility - Swansea
-
Truro, Vereinigtes Königreich, TR1 3LJ
- Royal Cornwall Hospital (Treliske)
-
-
Hertfordshire
-
Stevenage, Hertfordshire, Vereinigtes Königreich, SG1 4AB
- Lister Hospital
-
-
North Yorkshire
-
Pickering, North Yorkshire, Vereinigtes Königreich, YO18 8BL
- Pickering Medical Practice
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
- Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
- Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
- Body Mass Index (BMI) greater than or equal to 25 kilogram per square metre ( kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
Exclusion Criteria:
- Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m^2) as determined by central laboratory at screening.
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: CagriSema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of cagrilintide dose 1 and semaglutide dose 1 for 68 weeks. |
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached. Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached. |
|
Experimental: CagriSema Dose 2
Participants will receive once-weekly s.c injections of cagrilintide dose 2 and semaglutide dose 2 for 68 weeks. |
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached. Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached. |
|
Aktiver Komparator: Semaglutide Dose 1
Participants will receive once-weekly s.c injection of semaglutide dose 1 for 68 weeks. |
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached. |
|
Aktiver Komparator: Semaglutide Dose 2
Participants will receive once-weekly s.c injection of semaglutide dose 2 for 68 weeks. |
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached. |
|
Aktiver Komparator: Cagrilintide Dose 1
Participants will receive once-weekly s.c injection of cagrilintide dose 1 for 68 weeks. |
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached. |
|
Placebo-Komparator: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 1 and semaglutide dose 1 for 68 weeks. |
Participants will receive placebo matched to cagrilintide subcutaneously. Participants will receive placebo matched to semaglutide subcutaneously. |
|
Placebo-Komparator: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 2 and semaglutide dose 2 for 68 weeks. |
Participants will receive placebo matched to cagrilintide subcutaneously. Participants will receive placebo matched to semaglutide subcutaneously. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
CagriSema versus cagrilintide: Change in HbA1c
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus cagrilintide: Relative change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema (dose 1) versus semaglutide (dose 2): Change in HbA1c
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Relative change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage. |
From baseline (week 0) to end of treatment (week 68)
|
|
Cagrilintide versus placebo: Change in HbA1c
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
|
Cagrilintide versus placebo: Relative change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of greater than or equal to (>=) 10 percent (%) weight reduction
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of >= 15 % weight reduction
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of >= 20 % weight reduction
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL])
Zeitfenster: From baseline (week -3) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week -3) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL)
Zeitfenster: From baseline (week -3) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week -3) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Systolic Blood Pressure (SBP)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in triglycerides
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of triglycerides. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of non-HDL cholesterol. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Zeitfenster: From baseline (week -3) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week -3) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of hsCRP. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Fasting Plasma Glucose (FPG)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in mmol/L. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Zeitfenster: At end of treatment (week 68)
|
Measured as count of participants. |
At end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol)
Zeitfenster: At end of treatment (week 68)
|
Measured as count of participants. |
At end of treatment (week 68)
|
|
CagriSema versus semaglutide: CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in percentage-points. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: CGM - Within-day glycaemic variability (% coefficient of variation [CV])
Zeitfenster: At end of treatment (week 68)
|
Measured in percentage. |
At end of treatment (week 68)
|
|
CagriSema versus semaglutide: Achievement of ≥ 5 % weight reduction
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in waist circumference
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in centimetre. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Diastolic Blood Pressure (DBP)
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in total cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of total cholesterol. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in HDL cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of HDL cholesterol. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in low-density lipoprotein (LDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of LDL cholesterol. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of VLDL. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Ratio to baseline in free fatty acids
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
Measured as ratio of free fatty acids. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Short Form (SF)-36v score- Physical component summary score
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in SF-36v2 score- Mental component summary score
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide: Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score
Zeitfenster: From baseline (week 0) to end of treatment (week 68)
|
TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state. |
From baseline (week 0) to end of treatment (week 68)
|
|
CagriSema versus semaglutide, placebo and cagrilintide: Number of treatment emergent adverse events (TEAEs)
Zeitfenster: From baseline (week 0) to end of study (week 75)
|
Measured as count of events. |
From baseline (week 0) to end of study (week 75)
|
|
CagriSema versus semaglutide: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Zeitfenster: From baseline (week 0) to end of study (week 75)
|
Measured as count of episodes. |
From baseline (week 0) to end of study (week 75)
|
|
CagriSema versus semaglutide: Number of severe hypoglycaemic episodes (level 3)
Zeitfenster: From baseline (week 0) to end of study (week 75)
|
Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold. |
From baseline (week 0) to end of study (week 75)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NN9388-4896
- U1111-1283-0427 (Andere Kennung: World Health Organization (WHO))
- 2022-502678-18 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .